Skip to Content

C1 Inhibitor (Human)


(cee won in HIB i ter HYU man)

Index Terms

  • C1 Esterase Inhibitor
  • C1-INH
  • C1-Inhibitor
  • Human C1 Inhibitor

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Kit, Intravenous:

Berinert: 500 units

Solution Reconstituted, Intravenous [preservative free]:

Cinryze: 500 units (1 ea)

Solution Reconstituted, Subcutaneous:

Haegarda: 2000 units (1 ea); 3000 units (1 ea)

Brand Names: U.S.

  • Berinert
  • Cinryze
  • Haegarda

Pharmacologic Category

  • Blood Product Derivative
  • C1 Esterase Inhibitor


C1 inhibitor, one of the serine proteinase inhibitors found in human blood, plays a role in regulating the complement and intrinsic coagulation (contact system) pathway, and is also involved in the fibrinolytic and kinin pathways. C1 inhibitor therapy in patients with C1 inhibitor deficiency, such as HAE, is believed to suppress contact system activation via inactivation of plasma kallikrein and factor XIIa, thus preventing bradykinin production. Unregulated bradykinin production is thought to contribute to the increased vascular permeability and angioedema observed in HAE.


Berinert: Vss: Children and Adolescents: (6 to 13 years, n=5): 0.02 L/kg (range: 0.017 to 0.026 L/kg); Adults: 0.018 L/kg (range: 0.011 to 0.028 L/kg)

Haegarda: Vd: Adolescents and Adults: 0.05 L/kg

Onset of Action

Berinert: Onset of symptom relief: Median: 15 minutes per attack; Cinryze: Pediatric patients 6 to 17 years: Median: 30 minutes per attack; for the majority of patient unequivocal symptom relief reported within 1 hour (range: 15 to 135 minutes) (Lumry 2013)

Cinryze: Increased plasma C1 inhibitor levels observed ~1 hour or less

Time to Peak

Cinryze: ~4 hours; Haegarda: 59 hours

Duration of Action

Time to complete resolution of HAE symptoms: Berinert: Median: 8.4 hours

Half-Life Elimination


Children and Adolescents (6 to 13 years, n=5): 22 hours (range: 20 to 24 hours)

Adults (following a single dose): 22 hours (range: 17 to 24 hours)

Cinryze: Adults: 56 hours (range: 11 to 108 hours)

Haegarda: Adolescents and Adults: 69 hours

Use: Labeled Indications

Hereditary angioedema:

Berinert: Treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) in adults and pediatric patients.

Cinryze, Haegarda: Routine prophylaxis against angioedema attacks in adults and adolescents with HAE.


History of anaphylactic or life-threatening hypersensitivity reactions to human C1 inhibitor or any component of the formulation

Dosing: Adult

Hereditary angioedema (HAE) attacks, routine prophylaxis:

Cinryze: IV: 1,000 units every 3 to 4 days; doses ≤2,500 units (≤100 units/kg) every 3 or 4 days may be considered based on individual patient response.

Haegarda: SubQ: 60 units/kg every 3 or 4 days.

HAE attacks (abdominal, facial or laryngeal), treatment (Berinert): IV: 20 units/kg

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Hereditary angioedema (HAE) attacks, routine prophylaxis (Cinryze, Haegarda): Adolescents: Refer to adult dosing.

HAE attacks (abdominal, facial or laryngeal), treatment (Berinert): Children and Adolescents: Refer to adult dosing.

Dosing: Renal Impairment

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).

Dosing: Hepatic Impairment

There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).


Allow vial and diluent (SWFI) to come to room temperature prior to reconstitution. Reconstitute each vial with 5 mL (Cinryze 500 units), 10 mL (Berinert 500 units), 4 mL (Haegarda 2,000 units), 6 mL (Haegarda 3,000 units), or 3 mL (Berinert 1,500 units [Canadian product]) of SWFI using a double-ended transfer needle or the provided transfer set. A silicone-free syringe may be required for reconstitution (refer to manufacturer's labeling). Do not use product if there is no vacuum in the vial. After combining with diluent, gently swirl vial (do not shake) to completely dissolve powder. Reconstituted product should be clear and colorless or slightly blue (Cinryze only); do not use if turbid, discolored, or contains particles. The provided filter needle or transfer set should be used to withdraw the reconstituted product. Remove filter needle and attach reconstituted solution to infusion set or appropriate needle for infusion. Do not mix with other medicinal products.



Berinert (500 units): Administer intravenously at ~4 mL/minute by a separate infusion line.

Berinert (1,500 units) [Canadian product]: Administer intravenously by slow injection by a separate infusion line.

Cinryze (500 units): Administer intravenously at 1 mL/minute; (as a guideline, administer 1,000 units over 10 minutes)


Haegarda (2,000 or 3,000 units): For SubQ injection only in the abdominal area or other SubQ injection sites. Rotate injection sites.

Self-administration: Following patient training and instructions on self-administration, patient may self-administer treatment (Berinert) or prophylaxis (Cinryze, Haegarda) therapy. Epinephrine should be available during self-administration in the event of an acute, severe hypersensitivity reaction. Patient suffering from an acute laryngeal hereditary angioedema (HAE) attack and self-administering should be informed to seek immediate medical attention following treatment (potential for airway obstruction to occur).

A silicone-free syringe may be required for administration (refer to manufacturer's labeling).


Berinert, Cinryze: Store intact vials at 2°C to 25°C (36°F to 77°F); do not freeze. Store in original carton; protect from light. Use within 3 hours (Cinryze) or 8 hours (Berinert) of reconstitution (Canadian labeling recommends immediate use after reconstitution); do not refrigerate or freeze reconstituted solution. Discard any unused product.

Haegarda: Store intact vials at ≤30°C (86°F); do not freeze. Store in original carton; protect from light. Use within 8 hours of reconstitution; do not refrigerate or freeze reconstituted solution. Discard any unused product.

Drug Interactions

Androgens: May enhance the thrombogenic effect of C1 inhibitors. Monitor therapy

Estrogen Derivatives: May enhance the thrombogenic effect of C1 inhibitors. Monitor therapy

Progestins: May enhance the thrombogenic effect of C1 inhibitors. Monitor therapy

Adverse Reactions


Central nervous system: Headache

Gastrointestinal: Nausea

Local: Injection site reaction (35%)

Respiratory: Nasopharyngitis (19%)

1% to 10%:

Central nervous system: Dizziness

Dermatologic: Erythema, pruritus, skin rash

Gastrointestinal: Abdominal distress, abdominal pain, dysgeusia, vomiting, xerostomia

Hypersensitivity: Hypersensitivity reaction (7%), angioedema (including exacerbation of hereditary angioedema)

Infection: Fungal infection (vulvovaginal), viral infection

Respiratory: Flu-like symptoms, upper respiratory tract infection

Miscellaneous: Fever, infusion-related reaction

<1%, postmarketing, and/or case reports: Anaphylaxis, anxiety, cerebrovascular accident, chest pain, chills, deep vein thrombosis, diarrhea, fatigue, malaise, migraine, pain, shock, sinusitis, swelling, thrombosis, transient ischemic attacks, urticaria


Concerns related to adverse effects:

• Hypersensitivity: Severe hypersensitivity reactions (eg, urticaria, hives, tightness of the chest, wheezing, hypotension, anaphylaxis) may occur during or after administration. Signs/symptoms of hypersensitivity reactions may be similar to the attacks associated with hereditary angioedema, therefore, consideration should be given to treatment methods. In the event of acute or severe hypersensitivity reactions, discontinue treatment immediately.

• Thrombotic events: Serious arterial and venous thromboembolic events have been reported at recommended intravenous doses and when used off-label at doses higher than recommended. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Consider potential risk of thrombosis with use, and closely monitor patients with preexisting risks for thrombotic events.

Dosage form specific issues:

• Human plasma: Product of human plasma; may potentially contain infectious agents (eg, viruses, the variant Creutzfeldt-Jakob disease [vCJD] agent and, theoretically, the Creutzfeldt-Jakob disease [CJD] agent) that could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces the risk. Infections thought to be transmitted by this product should be reported to the manufacturer.

Other warnings/precautions:

• Self-administration: Due to the potential for airway obstruction, patients suffering from an acute laryngeal hereditary angioedema (HAE) attack and self-administering should be informed to immediately seek medical attention following treatment.

Monitoring Parameters

Signs/symptoms of hypersensitivity reactions and thrombotic events.

Pregnancy Risk Factor


Pregnancy Considerations

Animal reproduction studies have not been conducted. Although information related to use during pregnancy is limited, plasma-derived human C1 inhibitor concentrate is the preferred treatment for HAE during pregnancy (Baker 2013; Caballero 2012). Women with HAE should be monitored closely during pregnancy and for at least 72 hours after delivery (Caballero 2012).

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Patient may experience injection site irritation, rhinitis, pharyngitis, nausea, vomiting, or bad taste. Have patient report immediately to prescriber signs of blood clots (numbness or weakness on one side of the body; pain, redness, tenderness, warmth, or swelling in the arms or legs; change in color of an arm or leg; angina; shortness of breath; tachycardia; or coughing up blood), signs of severe cerebrovascular disease (change in strength on one side is greater than the other, difficulty speaking or thinking, change in balance, or vision changes), severe dizziness, passing out, severe headache, mouth discoloration, or tachycardia (HCAHPS).

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.